Author:
Sugimura Haruhiko,Yamada Hidetaka,Kageyama Shinji,Yamamura Yasuhiro,Yokota Naoki,Mori Hiroki,Iwaizumi Moriya,Shinmura Kazuya,Kurachi Kiyotaka,Nakamura Toshio,Tsuboi Masaru,Maekawa Masato,Kahyo Tomoaki
Reference35 articles.
1. Achatz MI, Hainaut P, Ashton-Prolla P (2009) Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol 10:920–925
2. Bogler O, Huang HJ, Kleihues P, Cavenee WK (1995) The p53 gene and its role in human brain tumors. Gila 15:308–327
3. Burger PC, Scheithauer BW (2007) Tumor of the central nervous system, vol 7. American Registry of Pathology and Armed Forces Institute of Pathology, Washington, DC
4. Goi K, Takagi M, Iwata S, Delia D, Asada M, Donghi R, Tsunematsu Y, Nakazawa S, Yamamoto H, Yokota J, Tamura K, Saeki Y, Utsunomiya J, Takahashi T, Ueda R, Ishioka C, Eguchi M, Kamata N, Mizutani S (1997) DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res 57:1895–1902
5. Hussain SP, Hollstein MH, Harris CC (2000) p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann NY Acad Sci 919:79–85